Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, announced today that it has received a notification letter from theNasdaqHearings Panel (the “Panel”) granting its request for continued listing on The Nasdaq Stock Market (“Nasdaq”) through January 15, 2025, subject […]